Q2 EPS Estimates for Trevi Therapeutics Lowered by B. Riley

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities research analysts at B. Riley dropped their Q2 2025 earnings per share estimates for shares of Trevi Therapeutics in a research note issued on Wednesday, March 19th. B. Riley analyst M. Mamtani now anticipates that the company will earn ($0.16) per share for the quarter, down from their previous forecast of ($0.14). B. Riley currently has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.49) per share. B. Riley also issued estimates for Trevi Therapeutics' Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.69) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($0.95) EPS, FY2028 earnings at ($1.10) EPS and FY2029 earnings at ($1.17) EPS.

A number of other equities research analysts have also recently commented on the stock. HC Wainwright reiterated a "buy" rating and set a $12.50 price target on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Oppenheimer increased their target price on Trevi Therapeutics from $12.00 to $20.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. D. Boral Capital restated a "buy" rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC dropped their price objective on Trevi Therapeutics from $25.00 to $24.00 and set a "buy" rating on the stock in a research report on Wednesday, March 19th. Finally, Raymond James upgraded Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and lifted their price objective for the stock from $9.00 to $29.00 in a report on Monday, March 10th. Seven investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Trevi Therapeutics has a consensus rating of "Buy" and a consensus price target of $17.56.

Remove Ads

Trevi Therapeutics Trading Up 3.3 %

NASDAQ:TRVI traded up $0.21 on Friday, reaching $6.61. 1,053,002 shares of the stock traded hands, compared to its average volume of 997,669. The company has a market capitalization of $639.07 million, a price-to-earnings ratio of -15.02 and a beta of 0.90. Trevi Therapeutics has a 12 month low of $2.30 and a 12 month high of $7.39. The company's fifty day simple moving average is $4.70 and its 200 day simple moving average is $3.81.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.01.

Insiders Place Their Bets

In other news, insider Farrell Simon sold 81,313 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the sale, the insider now directly owns 76,900 shares in the company, valued at $519,075. This represents a 51.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Jennifer L. Good sold 5,263 shares of Trevi Therapeutics stock in a transaction on Friday, March 21st. The shares were sold at an average price of $6.58, for a total value of $34,630.54. Following the transaction, the chief executive officer now owns 213,313 shares in the company, valued at $1,403,599.54. This trade represents a 2.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 24.37% of the company's stock.

Institutional Trading of Trevi Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of TRVI. Frazier Life Sciences Management L.P. grew its stake in shares of Trevi Therapeutics by 44.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company's stock valued at $43,939,000 after acquiring an additional 3,283,684 shares during the period. Woodline Partners LP boosted its position in shares of Trevi Therapeutics by 429.9% in the fourth quarter. Woodline Partners LP now owns 3,212,597 shares of the company's stock worth $13,236,000 after purchasing an additional 2,606,370 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of Trevi Therapeutics in the fourth quarter worth $58,000. Two Sigma Advisers LP bought a new stake in shares of Trevi Therapeutics during the 4th quarter valued at $66,000. Finally, Two Sigma Investments LP bought a new stake in shares of Trevi Therapeutics during the 4th quarter valued at $560,000. Hedge funds and other institutional investors own 95.76% of the company's stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.